Medical management of adrenocortical carcinoma: Current recommendations, new therapeutic options and future perspectives.
Adrenal Cortex Neoplasms
/ drug therapy
Adrenocortical Carcinoma
/ drug therapy
Antineoplastic Combined Chemotherapy Protocols
/ classification
Drugs, Investigational
/ therapeutic use
Endocrinology
/ methods
Humans
Medical Oncology
/ methods
Practice Guidelines as Topic
Therapies, Investigational
/ methods
Adrenal
Cancer
Chemotherapy
Chimiothérapie
Immunotherapy
Immunothérapie
Mitotane
Surrénales
Journal
Annales d'endocrinologie
ISSN: 2213-3941
Titre abrégé: Ann Endocrinol (Paris)
Pays: France
ID NLM: 0116744
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
29
11
2020
accepted:
01
12
2020
pubmed:
7
12
2020
medline:
27
10
2021
entrez:
6
12
2020
Statut:
ppublish
Résumé
Adrenocortical carcinoma is a rare malignant tumor of poor prognosis, frequently requiring additional treatments after initial surgery. Due to its adrenolytic action, mitotane has become the first-line medical treatment in patients with aggressive adrenocortical carcinoma. Over the last 2years, apart from the classical chemotherapy based on etoposide and platinum salts, several studies reported the use of drugs such as temozolomide, tyrosine kinase inhibitors or immunotherapy, with more or less convincing results. The aim of this review is to give further insights in the use of these drugs, and to describe potential therapeutic perspectives based on recent pangenomic studies, for the future management of these still difficult to treat tumors.
Identifiants
pubmed: 33279475
pii: S0003-4266(20)31307-X
doi: 10.1016/j.ando.2020.12.003
pii:
doi:
Substances chimiques
Drugs, Investigational
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
52-58Informations de copyright
Copyright © 2020 Elsevier Masson SAS. All rights reserved.